Healthcare / Diagnostics & ResearchASX
$0.06
-0.01 (-7.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.4M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$38M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-46.0%
↓Gross Margin
47.5%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+49.5%
FCF CAGR
—
FCF margin
-95.2%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.7M · net income $-14.9M · FCF $-14.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.7M | $15.7M | $12.1M | $5.4M | $4.7M |
| Net Income | $-14.9M | $-14.9M | $-19.9M | $-12.7M | $-11.5M |
| EBITDA | $-10.5M | $-10.5M | $-17.1M | $-11.0M | $-9.9M |
| EPS | -0.03 | -0.03 | -0.05 | -0.04 | -0.05 |
| Gross Margin | 47.5% | 47.5% | 48.8% | 49.4% | 50.5% |
| Operating Margin | -157.1% | -157.1% | -222.0% | -373.2% | -347.1% |
| Net Margin | -95.3% | -95.3% | -164.9% | -233.9% | -244.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.04 | 0.03 | 0.04 |
| Current Ratio | 1.73 | 1.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.9M | $-14.9M | $-19.9M | $-15.4M | $-12.3M |
| Returns | |||||
| ROE | -46.0% | -46.0% | -48.4% | -32.9% | -34.2% |
| Valuation | |||||
| P/B | 0.87 | 0.87 | 1.69 | 2.53 | 1.50 |
| Growth & Yield | |||||
| Revenue Growth | 29.6% | 29.6% | 123.1% | 15.6% | — |
| EPS Growth | 31.5% | 31.5% | -27.8% | 21.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.03
Residual
-49.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.